Bone Turnover
VIDEO: Bone turnover markers useful for monitoring effects of osteoporosis therapies
SANTA FE, N.M. — In this video exclusive, Jacques P. Brown, MD, discusses clinical applications of bone turnover markers in managing osteoporosis.
Use of SGLT2 inhibitors may not increase fracture risk in patients with CKD
While SGLT2 inhibitors are often associated with bone and mineral metabolism irregularities, it remains unclear if these are linked to higher fracture risk in patients with chronic kidney disease, according to recently published research.
Top in endocrinology: Menopausal hormone therapy; bone turnover markers and mortality risk
The North American Menopause Society released an updated position statement confirming that the benefits of menopausal hormone therapy outweigh the risks for most women.
High levels of bone turnover markers increase risk for all-cause mortality in older men
Older men with higher concentrations of three bone turnover markers have a higher risk for all-cause mortality than those with lower concentrations, according to study findings published in the Journal of Bone and Mineral Research.
Abaloparatide increases BMD, improves bone turnover markers in men with osteoporosis
SAN DIEGO — Men with osteoporosis receiving daily injections of abaloparatide had greater increases in bone mineral density at the lumbar spine, total hip and femoral neck at 12 months compared with placebo, according to a speaker.
Sclerostin biomarker signature effectively predicts women will develop osteoporosis
An effective way to predict a woman aged 25 to 31 years will develop osteoporosis is to do a check of sclerostin and possibly other blood serum markers for bone turnover at key timepoints in the woman’s life, according to a presenter.